

# **Virtual Histology: An Update and How It Might Be Used in Clinical Practice**

***Gary S. Mintz, MD***


**Cardiovascular Research Foundation  
New York, NY**

# Eagle Eye (20MHz Electronic Array Transducer)

VH IVUS vs histopathology from fresh 51 fresh, post mortem LADs (115 sections and 407 regions of interest)

	Sensitivity	Specificity	Predictive Accuracy
<b>Fibrous tissue (n=162)</b>	84.0%	98.8%	92.8%
<b>Fibrofatty (n=84)</b>	86.9%	95.1%	93.4%
<b>Necrotic core (n=69)</b>	97.1%	93.8%	94.4%
<b>Dense calcium (n=92)</b>	97.8%	99.7%	99.3%

# Change in non-culprit lesion phenotype in 106 patients (201 lesions) with plaque burden >40% from the Global VH Registry with baseline and 8-month follow-up VH analysis



Pathological  
intimal  
thickening (PIT)

Thin-cap  
fibroatheroma  
(TCFA)

Thick-cap  
fibroatheroma  
(ThFA)



Fibrotic

Fibrocalcific




# Thin Cap Fibroatheroma (TCFA)


“Thin Cap Fibro-Atheroma (TCFA)” or “Vulnerable Plaque” – Confluent necrotic core >10% of total plaque and located at the lumen in 3 consecutive frames. Based on the presence or absence of Ca, the length of the NC, or signs of previous ruptures, TCFA can be further sub-classified for the purpose of risk assessment



<5% calcium





>5% calcium



multiple layers

Still further sub-classification can be based on presence of luminal narrowing.

“TCFA without significant narrowing” - plaque burden <50% on IVUS and/or less than 25% narrowing on angiogram. (Pathologic data suggests that TCFA without significant plaque burden are less “vulnerable”)



“Highest Risk TCFA”

- a. Confluent NC>20%
- b. No evidence of fibrotic cap
- c. Calcium >5%
- d. Remodeling index >1.05
- e. >50% plaque burden by IVUS

(Pathologic data suggests that TCFA with significant plaque burden are the most vulnerable)

# The PROSPECT Trial

## 3-vessel imaging post PCI

Culprit artery, followed by non-culprit arteries

Angiography (QCA of entire coronary tree)

IVUS

Virtual histology

Palpography (n=~350)

*Proximal 6-8  
cm of each  
coronary  
artery*

Meds rec

Aspirin

Plavix 1yr

Statin

Repeat biomarkers

@ 30 days, 6 months

F/U: 1 mo, 6 mo,  
1 yr, 2 yr,  
±3-5 yrs

MSCT

Substudy

N=50-100

Repeat imaging  
in pts with events





CARDIOVASCULAR RESEARCH  
FOUNDATION





COLUMBIA UNIVERSITY  
MEDICAL CENTER


# PROSPECT: MACE



# PROSPECT: NCL MACE



# 3-year follow-up MACE





	All	Culprit lesion related	Non culprit lesion related	Indeter- minate
Cardiac death	1.9% (12)	0.2% (1)	0% (0)	1.8% (11)
Cardiac arrest	0.5% (3)	0.3% (2)	0% (0)	0.2% (1)
MI (STEMI or NSTEMI)	3.3% (21)	2.0% (13)	1.0% (6)	0.3% (2)
Unstable angina	8.0% (51)	4.5% (29)	3.3% (21)	0.5% (3)
Increasing angina	14.5% (93)	9.2% (59)	8.5% (54)	0.3% (2)
<b>Composite MACE</b>	<b>20.4% (132)</b>	<b>12.9% (83)</b>	<b>11.6% (74)</b>	<b>2.7% (17)</b>
Cardiac death, arrest or MI	4.9% (31)	2.2% (14)	1.0% (6)	1.9% (12)

Rates are 3-yr Kaplan-Meier estimates (n of events)




# Correlates of Non Culprit Lesion Related Events




Lesion HR	5.0 (2.9, 8.7)	6.7 (3.4, 13.0)	10.8 (4.3, 27.12)
P-value	<0.0001	<0.0001	<0.0001
Prevalence*	49.1%	15.4%	4.6%


\*Likelihood of one or more such lesions being present per patient. PB = plaque burden at the MLA






# Imaging Summary




In 615/697 pts with a mean of 2.6 (19.3cm) epicardial arteries imaged  
**≈2700 NC IVUS lesions w/ plaque burden >40% (4.5/pt)**





K-S  
29 Aug 1936  
3215/B/08

Szpital Uniwersytecki w Krakowie  
15 Oct 2008  
15:09:14



Il size 160.0 mm  
Lao 31.1 Caud -0.1  
Zoom (1.000x)

C:125 W:168  
99/160





CARDIOVASCULAR RESEARCH  
FOUNDATION




COLUMBIA UNIVERSITY  
MEDICAL CENTER






culprit of the culprit  
proximal to MLA



MLA



CARDIOVASCULAR RESEARCH  
FOUNDATION



COLUMBIA UNIVERSITY  
MEDICAL CENTER



# Thrombus

- A total of 259 in vitro histology slices were obtained and pathological thrombus was detected in 81 slices. Intramural thrombus was colored as fibrous or fibro-fatty by VH-IVUS, reducing the VH accuracy in these kinds of lesions.
  - Nasu et al Am J Cardiol 2008;101:1079-83
- As a result. . .
  - Superficial thrombus will cause a TCFA to be classified as a ThFCA
  - A thrombus-containing lesion may be classified as PIT or fibrotic (stable) rather than unstable

# Numerous studies have shown a relationship between VH-IVUS plaque composition and post-PCI distal embolization

## vs Nectoric Core


- Kawaguchi et al. J Am Coll Cardiol. 2007;50:1641-6
  - ST re-elevation in 71 pts with STEMI
- Kawamoto et al. J Am Coll Cardiol. 2007;50:1635-40
  - Doppler FloWire high intensity transit signals in 44 pts undergoing elective stenting resulting in poor recovery of CVFR
- Park et al. VH Summit 2007 (unpublished)
  - Largest NC independent predictor of CK-MB release (n=332)
- Hong et al. J Am Coll Cardiol Img, 2009;2:458-468
  - Troponin post elective stenting in 80 pts (29 stable and 51 unstable angina)
- Bose et al. Basic Res Cardiol 2008;103:587-97
  - CK and Tnl in 55 pts undergoing direct stenting. Patients in the 4th quartile of NC volume had a particularly high increase in biomarkers.
- Higashikuni et al. Circ J 2008; 72: 1235-41
  - No reflow in 49 pts with ACS undergoing PCI
- Hong et al. Eur Heart J, in press
  - No reflow in 190 pts with ACS undergoing stenting

## vs Fibrotic or Fibrofatty Plaque

- Bae et al. Heart. 2008;94:1559-64.
  - Multivariate analysis revealed that fibrofatty volume over the entire lesion length was the only independent predictor for slow flow during primary PCI in 57 pts with STEMI
- Nakamura et al. J Interv Cardiol. 2007;20:335-9
  - "Marble"-like image, mainly consisting of fibrofatty and fibrous plaque was associated with angiographic no-reflow in 50 STEMI pts undergoing primary PCI





# Attenuated Plaque





- Attenuated plaques were observed in 39.6% of STEMI, 17.6% of NSTEMI, and 0% of stable angina.
- Attenuate plaques were associated with more fibroatheromas and a larger necrotic core (on VH-IVUS).
- In ACS patients with attenuated plaques (1) the level of CRP was higher, (2) angiographic thrombus and initial coronary flow <TIMI 2 were more common, and (3) no-reflow or flow deterioration post-PCI were more common.


Attenuated  
Plaque




Non-attenuated  
plaque











- 114 consecutive patients who received elective stent implantations following IB-IVUS analysis were enrolled.
- The volume of each plaque component (lipid, fibrous, and calcified) was calculated for the target lesion.
- Creatine kinase-MB (CK-MB) and troponin-T (TnT) were evaluated 18 h after procedure.
- Post-procedural TnT level higher than three times the normal limit defined post-procedural myocardial injury.
- Lipid volume fraction (lipid volume/total plaque volume) correlated with post-procedural TnT and CK-MB.



- Patients with NSTEMI ACS who underwent OCT and successful emergent primary stenting were divided into two groups on the basis of post-stent TIMI flow: no-reflow group (n = 14) and reflow group (n = 69).
- Thin-cap fibroatheroma were more frequently observed in the no-reflow group than in the reflow group (50% vs. 16%,  $P = 0.005$ )
- The frequency of the no-reflow phenomenon increased according to the size of the lipid arc in the culprit plaque.
- Final TIMI blush grade also deteriorated according to the increase in the lipid arc.




Plaque contents  
passed downstream



Courtesy of Dr. Simon Dixon  
Beaumont Hospital, Royal Oak, MI



# Change in non-culprit lesion phenotype in 106 patients (201 lesions) with plaque burden >40% from the Global VH Registry with baseline and 8-month follow-up VH analysis



Pathological  
intimal  
thickening (PIT)

Thin-cap  
fibroatheroma  
(TCFA)


Thick-cap  
fibroatheroma  
(ThFA)

Fibrotic



Fibrocalcific




- During follow-up. . .
  - 75% of TCFAs healed and 25% remained unchanged although the location of the necrotic core in contact with the lumen shifted axially.
- Compared to TCFAs that healed, TCFAs that did not change were more proximal in location and had larger lumen area, vessel area, plaque area, calcium area, and necrotic core area.
- 12 new TCFAs were noted
  - 6 late-developing TCFAs were PIT and 6 were ThFA at baseline.
- No fibrotic or fibrocalcific plaques evolved into a TCFA.



Baseline





Follow-up



# IBIS-2: Effects of the direct Lp-PLA<sub>2</sub> inhibitor darapladib vs placebo on human coronary atherosclerotic plaque.


After 12 months, in the placebo-treated group NC volume increased significantly ( $\Delta\text{NC}=4.5\pm 17.9\text{mm}^3$ ,  $p=0.009$ ), whereas darapladib halted this increase ( $\Delta\text{NC}=-0.5\pm 13.9\text{mm}^3$ ,  $p=0.71$ ), resulting in a significant treatment difference of  $-5.2\text{mm}^3$  ( $p=0.012$ ) without a significant treatment difference in total atheroma volume or plaque deformability..




# Plaque Composition by IVUS - VH

## change from baseline in necrotic core volume

Entire region of interest  
[mean 48 mm]



The worst 10 mm  
subsegment




- placebo (plus standard of care) n=110
- darapladib 160 mg (plus standard of care) n=129




# Darapladib

Baseline



Follow-up



# Plaque behind Calcium

- 80% of regions of interest behind calcium contained a distinct low-amplitude signal that had a coherent periodic pattern on adjacent scan lines and a signal increase in the region of the adventitia indicating that this signal contained reflected ultrasound information as well as noise
- 20% of the regions of interest behind calcium had only noise
- Nevertheless, the signal level observed behind calcium is often very close to the noise level. Spectral assessment at such low signal-to-noise ratio might be unreliable, and VH data should be masked when a strong signal is followed by a very low intensity one or the algorithm should report a lower confidence (ala iMAP).


		Correct	Incorrect	ROIs	Accuracy
Mild microcalcium	IVG	2	0	2	100%
	S5	1	1	2	50%
Heavy microcalcium	IVG	3	6	9	33.3%
	S5	18	9	27	66.7%
Dense calcium	IVG	27	10	37	73%
	S5	27	16	43	62.8%
Overall	IVG	32	16	48	66.7%
	S5	46	26	72	63.9%

**Overall Accuracy: 65.0 %**


***When inaccurate, tissue is classified as NC  
(65% of the time), as FT (18% of the time),  
as FF (14% of the time)***



# iMAP



- Fibrotic
- Lipidic
- Necrotic
- Calcified





# iMAP

- 40MHz temporal and spatial resolution
- Not ECG-gated. Instead, 2 frames/mm are captured
- Output includes confidence limits - overall and regionally (i.e., behind calcium)
- Can analyze specific regions of interest, rather than just entire atheroma.
- RF data always acquired, even if just saved in the background for “posterity.” Can be “resurrected” and viewed at any time in the future.